UVA1 for Vitiligo

Phase-Based Progress Estimates
VitiligoUVA1 - Procedure
All Sexes
What conditions do you have?

Study Summary

This trial will test whether UVA1 phototherapy is an effective and safe treatment for vitiligo.

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment

Week 12
Assessment of side effects in each half including erythema, pruritus, and polymorphous light eruption
Change in the modified VASI score compared to baseline.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

No treatment (covered)
1 of 2
1 of 2

Active Control

16 Total Participants · 2 Treatment Groups

Primary Treatment: UVA1 · No Placebo Group · Phase 2

No treatment (covered)NoIntervention Group · 1 Intervention: No treatment (covered) · Intervention Types:
ActiveComparator Group · 1 Intervention: UVA1 · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,325 Previous Clinical Trials
1,534,077 Total Patients Enrolled
4 Trials studying Vitiligo
109 Patients Enrolled for Vitiligo
Harvey Lui, MD, FRCPCPrincipal InvestigatorUniversity of British Columbia
3 Previous Clinical Trials
64 Total Patients Enrolled
3 Trials studying Vitiligo
64 Patients Enrolled for Vitiligo

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have localized or generalized vitiligo that involves a non mucosal or acral site.